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A B S T R A C T
Aims: Mitochondria-targeted hydrogen sulﬁde donor AP39, [(10-oxo-10-(4-(3-thioxo-3H-1,2-dithiol-
5yl)phenoxy)decyl) triphenylphosphonium bromide], exhibits cytoprotective effects against oxidative stress
in vitro. We examined whether or not AP39 improves the neurological function and long term survival
in mice subjected to cardiac arrest (CA) and cardiopulmonary resuscitation (CPR).
Methods: Adult C57BL/6 male mice were subjected to 8 min of CA and subsequent CPR. We examined
the effects of AP39 (10, 100, 1000 nmol kg−1) or vehicle administered intravenously at 2 min before CPR
(Experiment 1). Systemic oxidative stress levels, mitochondrial permeability transition, and histological
brain injury were assessed. We also examined the effects of AP39 (10, 1000 nmol kg−1) or vehicle ad-
ministered intravenously at 1 min after return of spontaneous circulation (ROSC) (Experiment 2). ROSC
was deﬁned as the return of sinus rhythm with a mean arterial pressure >40 mmHg lasting at least 10
seconds.
Results: Vehicle treated mice subjected to CA/CPR had poor neurological function and 10-day survival
rate (Experiment 1; 15%, Experiment 2; 23%). Administration of AP39 (100 and 1000 nmol kg−1) 2 min
before CPR signiﬁcantly improved the neurological function and 10-day survival rate (54% and 62%, re-
spectively) after CA/CPR. Administration of AP39 before CPR attenuatedmitochondrial permeability transition
pore opening, reactive oxygen species generation, and neuronal degeneration after CA/CPR. Administra-
tion of AP39 1 min after ROSC at 10 nmol kg−1, but not at 1000 nmol kg−1, signiﬁcantly improved the
neurological function and 10-day survival rate (69%) after CA/CPR.
Conclusion: The current results suggest that administration of mitochondria-targeted sulﬁde donor AP39
at the time of CPR or after ROSC improves the neurological function and long term survival rates after
CA/CPR by maintaining mitochondrial integrity and reducing oxidative stress.
© 2015 Published by Elsevier Inc.
1. Introduction
The overall survival rate of resuscitated patients after out-of-
hospital CA is 7–10% in Europe and the United States [1] despite
the advances in CPR method [2] and post CA care [3]. In addition,
more than 50% of survivors have permanent neurological dysfunc-
tion of varying degrees [4,5]. Mitochondrial dysfunction following
ischemia/reperfusion (I/R) injury including CA and CPR is charac-
terized by an impairment of electron transport, generation of reactive
oxygen species (ROS) and decreased mitochondrial membrane po-
tential which leads to pro-apoptotic signaling and cell death [6–8].
No pharmacological agent has yet been found to improve clinical
outcomes after CA.
Hydrogen sulﬁde (H2S) mediates cytoprotective effects against
I/R injury at least in part via preservation of mitochondrial integ-
rity [9,10]. We previously reported that administration of sodium
sulﬁde (Na2S), a H2S generating compound, 1 min before the initi-
ation of CPR prevented neurological injury and improved survival
in mice subjected to CA and CPR [11,12]. While the beneﬁcial effects
of H2S after CA/CPR were later conﬁrmed by several investigators
[13,14], others failed to observe the protective effects of H2S donor
compounds [15,16]. Although reasons for the conﬂicting results are
undoubtedly multifactorial, at least a part of the problemmay relate
to the use of Na2S or sodium hydrosulﬁde (NaHS) as H2S donor com-
pounds in these studies. As these simple sulﬁde salts generate H2S
immediately in the solution, concentrations of H2S in prepared “H2S
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donor solution” are often unstable and unreliable [17]. Therefore,
the H2S concentrations in the target tissue (e.g., brain) are unpre-
dictable after bolus or continuous infusion of sulﬁde salts [18]. It
is imperative to develop H2S donor compounds that are targeted
to certain tissue or cellular organelle and release H2S in a more con-
trolled manner to translate the unique cytoprotective effects of H2S
into a useful drug. To this goal, we have recently developed a novel
mitochondria-targeted H2S donor, AP39. Mitochondria targeting is
achieved using a triphenylphosphonium (TPP+) conjugate, result-
ing in the compound being rapidly and extensively taken up by
mitochondria due to the electric potential gradient [19]. AP39 is also
highly lipophilic and is expected to readily permeate the cell mem-
brane [20]. AP39 increased the abundance of mitochondrial H2S and
protected cultured brain endothelial cells from oxidative stress at
doses less than 1/1000 of the conventional H2S generating com-
pounds (e.g, Na2S, NaHS, or GYY4137) [21,22].
We hypothesized that AP39 would protect brain mitochondrial
integrity in vivo and improve survival rate and neurological func-
tion after CA/CPR. To address this hypothesis, we examined the effect
of AP39 in the well-established murine CA/CPR model. Here, we
report that AP39, administered either before or after CPR, pre-
served brain mitochondrial integrity and improved long term
outcomes after CA in mice.
2. Methods
2.1. Animals and synthesis of AP39
After being approved by theMassachusetts General Hospital Sub-
committee on Research Animal Care, 8–10-week-old and weight-
matched male C57BL/6J wild type mice were included in the study.
To evaluate the effects of AP39, we assigned mice randomly to four
groups (AP39 at 10, 100 or 1000 nmol kg−1, and vehicle) in which
the study drug was administered 2 min before the initiation of CPR
(Experiment 1) and three groups (AP39 at 10 or 1000 nmol kg−1, and
vehicle) in which the study drugwas administered 1min after return
of spontaneous circulation (ROSC) (Experiment 2). AP39 was syn-
thesized in-house as described [23].
2.2. Animal preparation
Mice were anesthetized with 5% (v/v) isoﬂurane in 100% oxygen,
intubated, ventilated mechanically and maintained with 1.5% (v/
v) isoﬂurane. Temperature probe was inserted into the esophagus.
Arterial blood pressure was measured via the left femoral artery.
A microcatheter was inserted into the left femoral vein for drug ad-
ministration. The electrocardiogram was monitored with
subcutaneous needle electrodes.
2.3. Murine CA/CPR model
Cardiac arrest and CPR in mice were performed as previously de-
scribed with minor modiﬁcation [11,12]. Brieﬂy, CA was induced by
an administration of 0.08 mg g−1 body weight potassium chloride
via the left femoral vein and mechanical ventilation was stopped.
After 8 min of CA, chest compressions with a ﬁnger were deliv-
ered at a rate of 300–350 per minute. Mechanical ventilation with
100% oxygen and infusion of 0.6 μg min−1 adrenaline were initi-
ated 30 seconds before CPR. Chest compressions were continued
until ROSC was achieved when spontaneous heartbeat returns. In-
fusion of adrenaline was stopped at ROSC. Core body temperature
was maintained at 37.2 ± 0.1 °C throughout the surgical procedure
and 1 h after CPR. Mice were extubated and catheters were removed
1 h after CPR, then placed in a cage maintained at 30 °C by a heat
lamp for the following 2 hours.
2.4. Drug administration
AP39 was dissolved in 20% (v/v) dimethyl sulfoxide (DMSO) and
administered in the volume of 10 μl via the left femoral vein. Equiv-
alent volume of 20% (v/v) DMSO was administered as vehicle. AP39
or vehicle was administered 2 min before CPR in Experiment 1 and
1min after ROSC in Experiment 2, respectively. Synthesis and struc-
ture of AP39 was described elsewhere [23].
2.5. Assessment of neurological function
Neurological function at 48 h after CA/CPRwas assessed by a pre-
viously reported scoring system with minor modiﬁcations [12,24].
The system has ﬁve categories: consciousness, corneal reﬂex, res-
piration, coordination, and movement/activity. Each category was
scored as 0 (impaired), 1 (mild impaired), or 2 (normal). Total score
was reported as neurological function score.
2.6. Measurement of serum peroxide levels
Blood samples were collected 5 min after the initiation of CPR
or sham surgery and the concentrations of hydrogen peroxide in
serum were measured with QuantiChrom Peroxide Assay Kit
(BioAssay Systems, Hayward, CA, USA), as previously described [12].
Sham operated mice received the same procedure without CA.
2.7. Assessment of neuronal degeneration
Neuronal degeneration in the brain cortex and caudoputamen
(CPu) 48 h after CA/CPR was evaluated with the Fluoro-Jade B stain-
ing, as previously described [25]. The number of Fluoro-Jade B
positive cells per 1mm2 in the brain cortex and caudoputamenwere
calculated.
2.8. Assessment of mitochondria permeability transition pore
(mPTP) opening in brain cortical cells
To estimate the impact of AP39 treatment on mitochondrial in-
tegrity after CA/CPR, mPTP was evaluated in dissociated cortical cells
collected from mice 6 h after CA/CPR or naïve mice, using calcein–
cobalt quenching method as described previously [14]. Relative
ﬂuorescence intensity was then expressed as the ratio to the control
values obtained from naïve mice.
2.9. Measurement of H2S, thiosulfate, cysteine, and homocysteine
concentrations in the brain cortex
To determine the impact of CA and AP39 treatment on H2S me-
tabolism, concentrations of H2S, thiosulfate, cysteine, and
homocysteineweremeasured in the brain cortex collected frommice
30 min after CA/CPR or naïve mice using high performance liquid
chromatography (HPLC), as described previously [26,27]. In brief,
mice were euthanized and perfused with ice-cold Tris–HCl buffer
(pH 9.5, 0.1mM diethylenetriamine pentaacetic acid). Brain without
cerebellum was extracted, homogenized and centrifuged to obtain
supernatants. Then supernatants were derivatized with a ﬂuores-
cent labeling reagentmonobromobimane and analyzed by HPLCwith
a ﬂuorescence detector (Waters 2475 Multi λ ﬂuorescence detec-
tor, Waters, Milford, MA) equipped with Agilent 258 Eclipse XDB-
C18 column (Agilent Technologies, Santa Clara, CA, USA) at
wavelength of λex = 390 nm and λem = 475 nm.
2.10. Immunoblots
Brain cortex and liver tissue were obtained from mice 6 h after
CA/CPR or naïve mice. Protein levels of cystathionine c-lyase (CSE),
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3-mercapropyruvate sulfurtransferase (3MST), and cystathionine
b-synthase (CBS) in brain and liver homogenates were deter-
mined using standard immunoblot techniques using primary
antibodies against CSE (1:1,000; Proteintech, Chicago, IL, USA), 3MST
(1:1000; Sigma-Aldrich, St. Louis, MO, USA), CBS (1:2000; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), and GAPDH (1:10,000; Cell Sig-
naling Technology, Inc., Danvers, MA, USA). Bound antibody was
detected with a horseradish peroxidase-linked antibody directed
against rabbit IgG (1:10,000; Cell Signaling Technology, Inc.) and was
visualized using chemiluminescence with ECL Advance kit (GE
Healthcare Bioscience, Pittsburgh, PA, USA).
2.11. Statistical analysis
All values are expressed as mean ± standard error of the mean
(SEM). Parametric data were analyzed by one-way analysis of vari-
ance (ANOVA) with Newman–Keuls multiple comparison post hoc
test, Bonferroni’s post hoc test or two-way repeated measures
ANOVA with Bonferroni’s post hoc test. Differences in survival rates
were analyzed by log-rank test. Neurological function scores
were analyzed by Kruskal–Wallis test with Dunn’s post hoc test.
Numbers of Fluoro-Jade B positive cells were analyzed by un-
paired t-test with Welch’s correction. Probability values less
than 0.05 were considered signiﬁcant. Statistical analyses were per-
formed using GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla,
CA, USA).
3. Results
3.1. Administration of AP39 before CPR improves neurological
function and survival rate after CA/CPR (Experiment 1)
Arterial blood pressure at ROSC in mice treated with AP39
1000 nmol kg−1 was higher than in mice treated with AP39
10 nmol kg−1 (Supplementary Table S1). No mice died on and after
8 days after CA/CPR. Administration of AP39 at 100 or 1000 nmol kg−1,
but not at 10 nmol kg−1 at 2 min before CPR signiﬁcantly im-
proved survival rate at 10 days after CA/CPR (Fig. 1A). The
neurological function score 48 h after CA/CPR in mice treated with
AP39 at 100 or 1000 nmol kg−1 before CPR was signiﬁcantly better
than mice treated with vehicle (Fig. 1B).
3.2. Administration of AP39 before CPR attenuates hydrogen
peroxide generation in serum after CA/CPR
The concentrations of hydrogen peroxide in serum 5min after
CPR were increased in mice treated with Vehicle. Administration
of 1000 nmol kg−1 AP39 before CPR signiﬁcantly attenuated hydro-
gen peroxide levels in serum after CA/CPR (Fig. 2).
3.3. Administration of AP39 before CPR prevents neuronal
degeneration in brain cortex and caudoputamen at 48 h after CA/CPR
The number of Fluoro-Jade B positive cells in the brain cortex
and caudoputamen that indicates degenerated neurons were sig-
niﬁcantly increased in mice subjected to CA/CPR. Administration of
AP39 at 1000 nmol kg−1 before CPRmarkedly decreased the number
of Fluoro-Jade B positive cells compared tomice treated with vehicle
(Fig. 3A and B).
3.4. Administration of AP39 before CPR inhibits mPTP opening in the
brain mitochondria at 6 h after CA/CPR
Fluorescence intensity in mice treated with vehicle was signiﬁ-
cantly decreased 6 h after CA/CPR compared to naïvemice, suggesting
that mPTP was opened after CA/CPR. In contrast, ﬂuorescence in-
tensity in mice treated with AP39 at 1000 nmol kg−1 before CPR was
signiﬁcantly increased compared to mice treated with vehicle, sug-
gesting that AP39 inhibited mPTP opening after CA/CPR (Fig. 4).
Fig. 1. Survival rates and neurological function scores in Experiment 1. n = 13 in each
group. (A) Survival rate during the ﬁrst 10 days after CA/CPR. *P = 0.01 versus Vehicle.
(B) Neurological function scores at 48 h after CA/CPR. *P < 0.05 versus Vehicle.
Vehicle = mice treated with vehicle 2min before CPR. AP39 = mice treated with AP39
at 10, 100, or 1000 nmol kg−1 2 min before CPR.
Fig. 2. Serum hydrogen peroxide levels 5 minutes after CPR. n = 6 in each group. *P <
0.01 versus Sham. #P < 0.05 versus Vehicle. Sham = mice received sham proce-
dure without cardiac arrest. Vehicle = mice treated with vehicle 2 min before CPR.
AP39 = mice treated with AP39 at 1000 nmol kg−1 2 min before CPR.
ARTICLE IN PRESS
Please cite this article in press as: Kohei Ikeda, Eizo Marutani, Shuichi Hirai, Mark E. Wood, Matthew Whiteman, Fumito Ichinose, Mitochondria-targeted hydrogen sulfide donor
AP39 improves neurological outcomes after cardiac arrest in mice, Nitric Oxide (2015), doi: 10.1016/j.niox.2015.05.001
3K. Ikeda et al./Nitric Oxide ■■ (2015) ■■–■■
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
3.5. Administration of AP39 after ROSC improves neurological
function and survival rate after CA/CPR (Experiment 2)
Administration of AP39 at 10 nmol kg−1, but not at 1000 nmol kg−1,
1 min after ROSC signiﬁcantly improved the survival rate at 10 days
after CA/CPR (Fig. 5A). The neurological function score 48 h after CA/
CPR in mice treated with 10 nmol kg−1 AP39 after ROSC was
signiﬁcantly better than mice treated with vehicle (Fig. 5B).
3.6. Brain H2S concentration is decreased immediately after CA/CPR
H2S and thiosulfate concentrations in the brain 30 min after CA/
CPR were signiﬁcantly decreased in mice treated with vehicle
compared to naïve mice. Administration of AP39 at 1000 nmol kg−1
before CPR or 10 nmol kg−1 after ROSC restored brain H2S concen-
tration to the baseline levels observed in naïve mice (Fig. 6A).
Similarly the brain thiosulfate levels were restored by administra-
tion of AP39 at 10 nmol kg−1 after ROSC and markedly increased by
administration of AP39 at 1000 nmol kg−1 before CPR (Fig. 6B).
Whereas CA/CPR without or with AP39 treatment did not affect the
levels of cysteine and homocysteine (Fig. 6C and D).
3.7. Protein expression levels of CSE, 3MST, and CBS in the brain and
liver 6 h after CA/CPR
To elucidate the mechanisms responsible for the altered sulﬁde
metabolism, we examined the protein expression levels of CSE, 3MST,
and CBS in the brain and liver at baseline and 6 h after CA/CPR. The
protein expression levels of CSE, 3MST, and CBS in the brain and
liver did not differ among naïve mice and CA/CPR mice treated with
vehicle or AP39 (Supplementary Fig. S1).
Fig. 3. (A) Comparison of Fluoro-Jade B positive cells in the brain cortex and
caudoputamen 48 h after CA/CPR. Scale bar = 500 μm. (B) Number of Fluoro-Jade B
positive cells per 1 mm2 in the brain cortex and caudoputamen. n = 4 in each group.
*P = 0.03 versus Vehicle. #P = 0.02 versus Vehicle. Vehicle = mice treated with vehicle
2 min before CPR. AP39 = mice treated with AP39 at 1000 nmol kg−1 2 min before
CPR.
Fig. 4. mPTP opening in brain cortex 6 h after CA/CPR. n = 4 in each group. *P < 0.001
versus Naïve. #P < 0.05 versus Vehicle. Naïve = untreated naïve mice. Vehicle = mice
treated with vehicle 2 min before CPR. AP39 = mice treated with AP39 at
1000 nmol kg−1 2 min before CPR.
Fig. 5. Survival rates and neurological function scores in Experiment 2. n = 13 in each
group. (A) Survival rate during the ﬁrst 10 days after CA/CPR. *P = 0.006 versus Vehicle.
#P = 0.03 versus AP39 1000 nmol kg−1. (B) Neurological function scores 48 h after
CA/CPR. *P < 0.05 versus Vehicle and AP39 1000 nmol kg−1. Vehicle = mice treated
with vehicle 1min after ROSC. AP39 = mice treated with AP39 at 10 or 1000 nmol kg−1
1 min after ROSC.
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4. Discussion
The current study shows that administration of the
mitochondrial-targeted H2S donor compound AP39 exerts
neuroprotective effect after CA/CPR. The effectiveness of H2S on the
outcome following CA/CPR is controversial. We previously re-
ported that administration of Na2S at 7 μmol kg−1 markedly improved
the neurological outcomes and survival rate in mice subjected to
CA/CPR [11,12]. In contrast Derwall et al. reported that administra-
tion of Na2S at 3.8 μmol kg−1 bolus followed by infusion at
3.8 μmol kg−1 h−1 or at 12.8 μmol kg−1 bolus followed by infusion at
12.8 μmol kg−1 h−1 did not improve the survival rates and neuro-
logical function in swine [15]. Knapp and colleagues reported that
administration of Na2S at 6.4 μmol kg−1 bolus followed by infusion
at 12.8 μmol kg−1 h−1 reduced the sensorimotor deﬁcits 72 h after
CA/CPR in rats without improving survival rate [16]. The discrep-
ancy of these reports may be related to the differences in dosage
of Na2S, timing of administration, severity of ischemia, and animal
species. In particular, markedly higher doses of Na2S were used by
the studies by Derwall (total dose 38 μmol kg−1) and Knapp (total
dose 83 μmol kg−1) compared to our studies with Na2S in mice (total
dose 7 μmol kg−1).
It is important to note that the doses of AP39 required to improve
outcomes after CA/CPR were 3-orders of magnitude smaller than
the doses of Na2S found effective in the treatment of experimental
I/R injury including CA/CPR [11,14]. Since one mole of both AP39
and Na2S release one mole of H2S, this translates that sulﬁde con-
centration in the target tissue (e.g., brain) is likely to be 3-orders
of magnitude smaller after administration of AP39 than after Na2S.
It is well-known that high concentration of H2S is neurotoxic [28].
Simple sulﬁde salts such as Na2S spontaneously releases high con-
centrations of sulﬁde immediately upon administration. It is also
of note that administration of low dose AP39 after ROSC markedly
improved outcomes after CA/CPR, whereas post-CPR administra-
tion of Na2S was ineffective [12]. From the standpoint of translation,
effectiveness as a post treatment is highly clinically relevant.
Mitochondria generate ROS under hypoxic conditions [7,29] and
are both an origin and a target of cytotoxicity in I/R injury. It has
been reported that AP39 increased H2S generation in the mitochon-
dria, protected mitochondrial membrane potential and inhibited
oxidative-stress induced cell death in cultured human endothelial
cells [21,23]. In our experiments, administration of AP39 before
CPR also attenuated the increase of hydrogen peroxide levels in
serum after reperfusion (Fig. 2). These results suggest that AP39
treatment reduces neuronal damage through attenuation
of oxidative stress in vivo, possibly via protection of mitochondrial
integrity.
The mitochondrial permeability transition pore (mPTP) opening
results in mitochondrial dysfunction and leads to apoptotic or ne-
crotic cell death [30]. Although we previously found that Na2S
preventedmPTP opening of cardiac mitochondria after CA/CPR, Na2S
failed to protect the brain mitochondria [12]. The inhibitory effects
of AP39 on the CA-induced mPTP opening in the brain mitochon-
dria suggest that AP39 can permeate BBB after CA/CPR, although
Fig. 6. Concentrations of H2S (A), thiosulfate (B), cysteine (C), and homosysteine (D) in the brain cortex 30 min after CA/CPR. n = 7 in each group. *P < 0.05 versus Vehicle.
**P < 0.05 versus Naïve. #P < 0.05 versus AP39 1000 nmol kg−1. Naïve = untreated naïve mice. Vehicle = mice treated with vehicle 2 min before CPR. AP39 = mice treated with
AP39 at 1000 nmol kg−1 2 min before CPR or 10 nmol kg−1 1 min after ROSC.
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the permeability of AP39 across BBB remains to be formally
examined.
It has been reported that myocardial H2S levels were markedly
reduced after myocardial ischemia and reperfusion injury [31]. Sim-
ilarly, we found that brain levels of H2S and thiosulfate, but not
cysteine and homocysteine, were markedly decreased 30 min after
CA/CPR in the current study. We also observed that protein expres-
sion levels of CSE, CBS, and 3MST were not altered in the brain
and liver after CA/CPR. These results suggest that CA/CPR-induced
reduction in H2S levels is not due to increased oxidation of H2S to
thiosulfate or depressed H2S synthesis via transsulfuration enzymes.
Although the precise mechanism responsible for the reduction of
brain H2S levels after CA/CPR remains to be determined, maintain-
ing physiological levels of H2S may be critical for cell survival [31,32].
It is of note that the brain H2S concentrations achieved by
administration of AP39 at 1000 nmol kg−1 before CPR or 10 nmol kg−1
after ROSC were equivalent. The reason why two differing doses of
AP39 achieved similar brain H2S levels may be attributable to the
organ distribution of TPP+ conjugated compounds. It is likely that
signiﬁcant portion of AP39, especially administered before CPR, is
rapidly taken up into other organs including kidney, liver, heart
and fat before reaching the brain after intravenous injection during
CA [33].
In mitochondrial respiratory chain, high concentrations of H2S
inhibit cytochrome oxidase, resulting in a shutdown of mitochon-
drial electron transport and adenosine triphosphate (ATP) generation.
However, at lower concentrations, H2S has been shown to acceler-
ate ATP generation by acting as a stimulator of mitochondrial electron
transport [34]. In brain microvascular endothelial cells, AP39 in-
creased oxygen consumption ratio at 30 and 100 nM, but not at
300 nM, indicating the acceleration of electron transport at lower
doses [21]. It is tempting to speculate that the better survival and
neurological function after administration of AP39 at a low-dose,
but not at high-dose, after CPR, were associated with an accelera-
tion of mitochondrial ATP generation on demand after reoxygenation.
The current study was designed to determine whether or not
AP39 improves neurological outcomes in a clinically relevant mouse
model of CA/CPR. It is possible that AP39 directly protects neuro-
nal integrity, as suggested by our current results, but it is also
conceivable that AP39 prevents cardiovascular dysfunction after CA/
CPR thereby improves neurological outcomes via improved cerebral
perfusion. Further investigations are needed to establish the mecha-
nisms accounting for the protective effects of AP39 after CA/CPR.
5. Conclusions
In summary, we observed potent neuroprotective effects of the
mitochondrial-targeted H2S donor compounds AP39 in a mouse
model of CA/CPR. The dose of AP39 required to markedly improve
survival after CA/CPR in mice was 3 orders of magnitude smaller
than the dose of conventional H2S generating compound, Na2S. The
beneﬁcial effects of AP39 were associated with preservation of mi-
tochondrial integrity and reduced oxidative stress. The effectiveness
of AP39 administered after ROSC may be highly clinically relevant
and warrants further investigation.
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